NCT02742935View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Solid TumorBreast CancerGastrointestinal Cancer
Interventions
BIOLOGICAL

camrelizumab

A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02742935 - A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | Biotech Hunter | Biotech Hunter